Pediatric low-grade glioma (pLGG) is the most common form of pediatric brain cancer. Day One’s OJEMDA™ is the first targeted treatment for pLGG tumors with BRAF fusions and mutations. Last week, on April 23, 2024, Day One Biopharmaceuticals was granted Accelerated […]
The urgent need for advanced childhood brain cancer research G34R-mutant pediatric diffuse glioma, a devastating brain cancer affecting children and young adults, poses significant challenges in treatment due to its aggressive nature, limited therapeutic options, and the long-term side effects.
This Pediatric Glioma has no known cure. Dr. Breunig is Taking on the Challenge. Read More »
Neuroblastoma is the most common extracranial solid tumor of childhood arising within the developing nervous system. Approximately half of neuroblastoma patients are diagnosed with high-risk disease, which is especially aggressive with a 50% survival rate. If a child’s high-risk neuroblastoma
Acute Myeloid leukemia (AML) is the second most common leukemia in children, and the prognosis after relapse is poor. Unlike current CAR T treatment for the most common childhood leukemia, acute lymphoblastic leukemia (ALL), patients with AML experience significant toxicity
Dr. Moghimi is developing next-generation CAR T-cells to treat pediatric AML. Read More »
Funds to support cutting-edge immunotherapy trial for pediatric high-grade glioma Bethesda, MD – February 8, 2020 – CureSearch for Children’s Cancer has received a $1 million gift from the Norcross Family Foundation in support of a first-in-human, phase I/II clinical trial testing
CureSearch for Children’s Cancer receives gift to support promising immunotherapy trial Read More »
This year, we were proud to award new research grants supporting truly cutting-edge projects. We also know that smarter research funding is just one part of the solution, and that long-term impact will require strategic collaboration among all members of the
With your support, we’re bringing our kids to the forefront of drug development Read More »
“We were fortunate that CureSearch had just launched their Catapult Award program….It enabled researchers to access up to $2.5M in funding over three years, through a streamlined application process, rather than contending with multiple applications for smaller grants which would have lengthened
Contact: Tiffani CopelandSenior Vice President, Development & CommunicationsCureSearch for Children’s CancerEmail: tiffani.copeland@curesearch.org Bethesda, MD – July 30, 2020 – CureSearch for Children’s Cancer, in partnership with the SebastianStrong Foundation, has awarded a $225,000 Young Investigator grant to Yale Cancer Center’s
CureSearch Research Funding DrivesNew Brain Cancer Treatments May is National Brain Tumor Awareness Month, highlighting a critical topic in the childhood cancer community as brain cancers account for 25% of all childhood and adolescent cancer diagnoses. Brain tumor types include medulloblastoma (the most common), high- and low-grade glioma, Primitive
As we work to find new and less-toxic treatments for pediatric cancers, we know that smarter research funding is just one part of the solution. Long-term solutions require a seismic shift in the existing pediatric drug development process. This change
